Vomitinib, known as vomitinib mesylate tablets, has a median peak time of 4 hours after a single oral dose and a median peak time of 7-10 hours for the metabolite of vomitinib mesylate tablets (AsT5902) in patients with non-small cell lung cancer. This product is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer who have experienced disease progression on or after prior treatment with an epidermal growth factor receptor tyrosine kinase inhibitor and who have been tested and confirmed to have a positive EGFRT790M mutation. Adverse reactions such as rash and abnormalities in liver and kidney function can occur during vorametinib administration. It is contraindicated in patients who are allergic to the product. Patients should be guided by professional oncologists for specific medication to avoid adverse effects.